|
|
 Previous Article | Table of Contents | Next Article 
Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy
Elihu Estey,
Peter Thall,
Miloslav Beran,
Hagop Kantarjian,
Sherry Pierce, and
Michael Keating
From the Departments of Hematology and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX.
In current medical practice, patients with refractory anemia with excess blasts in transformation (RAEB-t), and especially patients with RAEB, receive chemotherapy regimens (AML Rx) administered to patients with acute myeloid leukemia (AML) less often than do patients with AML. These entities are distinguished primarily by marrow blast percentage (5% to 19% RAEB, 20% to 29% RAEB-t, and  30% AML). The poor prognosis of many RAEB or RAEB-t patients, if untreated, led us to give them AML Rx using the same plan as for AML. The purpose of this analysis was to see if diagnosis (RAEB, RAEB-t, or AML) affected outcome. We treated 372 patients with AML (acute promyelocytic leukemia [APL] excluded), 106 with RAEB-t, and 52 with RAEB. AML Rx produced a 62% complete remission (CR) rate in RAEB, essentially identical to the rates in RAEB-t and AML, but event-free survival (EFS) from CR and from start of treatment (start of Rx), as well as overall survival, were poorer in RAEB than in AML or RAEB-t, with AML and RAEB-t being identical. However, patients with RAEB or RAEB-t were more likely to have poor prognostic characteristics, in particular complex abnormalities involving chromosomes 5 and/or 7. Multivariate analyses indicated that, when considered together with cytogenetics and other patient characteristics, a diagnosis of RAEB rather than AML or RAEB-t had no effect on EFS from start of Rx, EFS from CR, survival, or achievement of CR. These analyses suggested a trend for patients with RAEB-t to have better EFS from start of Rx than patients with AML or RAEB (P = .08; relative risk, 0.80; 95% confidence interval, 0.62 to 1.03), but there were no differences with respect to the other outcomes. Our data suggest that the propriety of administering AML Rx to patients with RAEB or RAEB-t who have poor prognosis without treatment is identical to the propriety of treating AML in this fashion. Deterrents to standard AML Rx in these patients could justifiably include cytogenetics, age, etc, but not a diagnosis of RAEB or RAEB-t per se.
Blood, Vol. 90 No. 8 (July 15), 1997:
pp. 2969-2977
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. M. Stone
How I treat patients with myelodysplastic syndromes
Blood,
June 18, 2009;
113(25):
6296 - 6303.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Estey
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
J. Clin. Oncol.,
May 10, 2007;
25(14):
1908 - 1915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Lancet, I. Gojo, J. Gotlib, E. J. Feldman, J. Greer, J. L. Liesveld, L. M. Bruzek, L. Morris, Y. Park, A. A. Adjei, et al.
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Blood,
February 15, 2007;
109(4):
1387 - 1394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Jabbour, E. Estey, and H. M. Kantarjian
Adult Acute Myeloid Leukemia
Mayo Clin. Proc.,
February 1, 2006;
81(2):
247 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and J. M. Bennett
The Myelodysplastic Syndromes: Diagnosis and Treatment
Mayo Clin. Proc.,
January 1, 2006;
81(1):
104 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone, M. R. O'Donnell, and M. A. Sekeres
Acute Myeloid Leukemia
Hematology,
January 1, 2004;
2004(1):
98 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Vardiman, N. L. Harris, and R. D. Brunning
The World Health Organization (WHO) classification of the myeloid neoplasms
Blood,
September 18, 2002;
100(7):
2292 - 2302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Albitar, T. Manshouri, Y. Shen, D. Liu, M. Beran, H. M. Kantarjian, A. Rogers, I. Jilani, C. W. Lin, S. Pierce, et al.
Myelodysplastic syndrome is not merely "preleukemia"
Blood,
July 18, 2002;
100(3):
791 - 798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Estey, P. F. Thall, F. J. Giles, X.-M. Wang, J. E. Cortes, M. Beran, S. A. Pierce, D. A. Thomas, and H. M. Kantarjian
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
Blood,
May 29, 2002;
99(12):
4343 - 4349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian
Acute Myeloid Leukemia
Hematology,
January 1, 2002;
2002(1):
73 - 110.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. H. Estey, P. F. Thall, J. E. Cortes, F. J. Giles, S. O'Brien, S. A. Pierce, X. Wang, H. M. Kantarjian, and M. Beran
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts
Blood,
December 15, 2001;
98(13):
3575 - 3583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. de Witte, S. Suciu, G. Verhoef, B. Labar, E. Archimbaud, C. Aul, D. Selleslag, A. Ferrant, P. Wijermans, F. Mandelli, et al.
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS
Blood,
October 15, 2001;
98(8):
2326 - 2331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Gore, L.-J. Weng, S. Zhai, W. D. Figg, R. C. Donehower, G. J. Dover, M. Grever, C. A. Griffin, L. B. Grochow, E. K. Rowinsky, et al.
Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia
Clin. Cancer Res.,
August 1, 2001;
7(8):
2330 - 2339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Head
Problematic WHO Reclassification of Myelodysplastic Syndromes
J. Clin. Oncol.,
October 19, 2000;
18(19):
3447 - 3452.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Estey
How I treat older patients with AML
Blood,
September 1, 2000;
96(5):
1670 - 1673.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Albitar, M. Beran, S. O'Brien, H. Kantarjian, E. Frieriech, M. Keating, and E. Estey
Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia
Blood,
July 1, 2000;
96(1):
372 - 374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hellstrom-Lindberg, C. Willman, A. J. Barrett, and Y. Saunthararajah
Achievements in Understanding and Treatment of Myelodysplastic Syndromes
Hematology,
January 1, 2000;
2000(1):
110 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Estey, Y. Shen, and P. F. Thall
Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB
Blood,
January 1, 2000;
95(1):
72 - 77.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aguayo, E. Estey, H. Kantarjian, T. Mansouri, C. Gidel, M. Keating, F. Giles, Z. Estrov, B. Barlogie, and M. Albitar
Cellular Vascular Endothelial Growth Factor Is a Predictor of Outcome in Patients With Acute Myeloid Leukemia
Blood,
December 1, 1999;
94(11):
3717 - 3721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Beran, E. Estey, S. O'Brien, J. Cortes, C. A. Koller, F. J. Giles, S. Kornblau, M. Andreeff, N. Vey, S. R. Pierce, et al.
Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
J. Clin. Oncol.,
September 1, 1999;
17(9):
2819 - 2819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Heaney and D. W. Golde
Myelodysplasia
N. Engl. J. Med.,
May 27, 1999;
340(21):
1649 - 1660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Estey, P. F. Thall, S. Pierce, J. Cortes, M. Beran, H. Kantarjian, M. J. Keating, M. Andreeff, and E. Freireich
Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome
Blood,
April 15, 1999;
93(8):
2478 - 2484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Luna-Fineman, K. M. Shannon, S. K. Atwater, J. Davis, M. Masterson, J. Ortega, J. Sanders, P. Steinherz, V. Weinberg, and B. J. Lange
Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients
Blood,
January 15, 1999;
93(2):
459 - 466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
